Dear Duchenne Community,
This morning we issued a press release announcing some changes to our organizational structure. As part of our commitment to transparency we wanted to provide you with a bit more context.
As you may recall, in December we reported biomarker data from two patients that provide evidence that, while early, suggest SGT-001 may be an important and differentiated treatment for Duchenne. We are encouraged by the activity we saw and our commitment to SGT-001 remains strong. However, given an adverse event, IGNITE DMD was put on clinical hold and in order to effectively address the hold and evaluate SGT-001’s potential for patients, we had to make some tough choices to re-focus our resources. As part of the organizational changes, we will reduce our work force by approximately one third and curtail activities on our other research and development programs. We are grateful for the efforts and contributions of every employee who has worked tirelessly to advance our mission to improve the lives of patients with Duchenne.
While Solid will look a little different as we move into 2020, our commitment to the Duchenne community is unwavering. We will continue to work every day with resolve and urgency to determine the best path forward to resume dosing of SGT-001. Safety is our highest priority and as we learn more, we will share this information with the Duchenne community.
As always, we appreciate your continued support.
Your Solid Biosciences Team